European Medicines Agency Rejects Lecanemab for Early Alzheimer’s Disease, Citing Insufficient Benefit-Risk Profile.
The European Medicines Agency (EMA), through its expert Committee for Medicinal Products for Human Use (CHMP), has delivered a significant blow to the global fight against Alzheimer’s disease, announcing its…







